Here’s what to consider. Targeting the spike protein Pfizer’s JN.1 booster (and Moderna’s, though the TGA has not approved this one at this stage) is based on mRNA technology. This technology ...

So an annual COVID booster is not considered enough for some more vulnerable people. For adults aged 65 to 74 , a booster is ...